Works matching DE "BORTEZOMIB"
Results: 1560
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.
- Published in:
- Molecular & Cellular Biochemistry, 2014, v. 389, n. 1/2, p. 177, doi. 10.1007/s11010-013-1939-5
- By:
- Publication type:
- Article
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
- Published in:
- Molecular & Cellular Biochemistry, 2014, v. 385, n. 1/2, p. 265, doi. 10.1007/s11010-013-1835-z
- By:
- Publication type:
- Article
Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells.
- Published in:
- Biotechnology Letters, 2016, v. 38, n. 2, p. 357, doi. 10.1007/s10529-015-1968-0
- By:
- Publication type:
- Article
Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
- Published in:
- Biotechnology Letters, 2014, v. 36, n. 6, p. 1171, doi. 10.1007/s10529-014-1470-0
- By:
- Publication type:
- Article
Anti-tumor effect of dandelion flavone on multiple myeloma cells and its mechanism.
- Published in:
- Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01076-z
- By:
- Publication type:
- Article
HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00422-8
- By:
- Publication type:
- Article
EFFECT OF NORDIC WALKING TRAINING COMBINED WITH INTERMITTENT FASTING ON SERUM LEVELS OF WNT PATHWAY INHIBITORS IN PATIENTS WITH PLASMOCYTIC MYELOMA.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus.
- Published in:
- Global & Regional Health Technology Assessment, 2021, v. 8, n. 1, p. 80, doi. 10.33393/grhta.2021.2245
- By:
- Publication type:
- Article
The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes.
- Published in:
- Turkish Journal of Medical Sciences, 2016, v. 46, n. 6, p. 1882, doi. 10.3906/sag-1511-184
- By:
- Publication type:
- Article
An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.
- Published in:
- Turkish Journal of Medical Sciences, 2015, v. 45, n. 1, p. 38, doi. 10.3906/sag-1401-127
- By:
- Publication type:
- Article
多发性骨髓瘤患者硼替佐米治疗相关带状疱疹发病机理 及预防策略研究进展
- Published in:
- Progress in Modern Biomedicine, 2019, v. 19, n. 13, p. 2592, doi. 10.13241/j.cnki.pmb.2019.13.044
- By:
- Publication type:
- Article
Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma Mimicking as Plasma Cell Neoplasm: A Rare Case Report.
- Published in:
- Journal of Applied Hematology, 2023, v. 14, n. 3, p. 252, doi. 10.4103/joah.joah_40_23
- By:
- Publication type:
- Article
Approaches to Multiple Myeloma Management in Gulf Countries: A Narrative Review Insights from the Kingdom of Saudi Arabia and Gulf Multiple Myeloma Experts.
- Published in:
- Journal of Applied Hematology, 2023, v. 14, n. 2, p. 71, doi. 10.4103/joah.joah_110_22
- By:
- Publication type:
- Article
Management of Tumor Lysis Syndrome in Patients With Multiple Myeloma During Bortezomib Treatment.
- Published in:
- Clinical Journal of Oncology Nursing, 2015, v. 19, p. E4, doi. 10.1188/15.CJON.E4-E7
- By:
- Publication type:
- Article
Management of Tumor Lysis Syndrome in Patients With Multiple Myeloma During Bortezomib Treatment.
- Published in:
- Clinical Journal of Oncology Nursing, 2015, v. 19, n. 1, p. E4, doi. 10.1188/15.CJON.E4-E7
- By:
- Publication type:
- Article
The Changing Landscape of Multiple Myeloma.
- Published in:
- Clinical Journal of Oncology Nursing, 2013, v. 17, p. 7, doi. 10.1188/13.CJON.S2.7-11
- By:
- Publication type:
- Article
PP455 Cost-effectiveness Of Ixazomib-Based Regimen Compared With Bortezomib-Based Regimen In Chinese Patients With Relapsed/Refractory Multiple Myeloma: A Retrospective Study.
- Published in:
- 2020
- By:
- Publication type:
- Abstract
Bortezomib for antibody‐mediated rejection of kidney transplant in youth: Associations with donor‐specific antibody.
- Published in:
- Pediatric Transplantation, 2024, v. 28, n. 5, p. 1, doi. 10.1111/petr.14774
- By:
- Publication type:
- Article
Bortezomib for autoimmune hemolytic anemia after intestinal transplantation.
- Published in:
- Pediatric Transplantation, 2020, v. 24, n. 4, p. 1, doi. 10.1111/petr.13700
- By:
- Publication type:
- Article
Control of graft‐versus‐host disease with rabbit anti‐thymocyte globulin, rituximab, and bortezomib in TCRαβ/CD19‐depleted graft transplantation for leukemia in children: a single‐center retrospective analysis of two GVHD‐prophylaxis regimens
- Published in:
- Pediatric Transplantation, 2020, v. 24, n. 1, p. N.PAG, doi. 10.1111/petr.13594
- By:
- Publication type:
- Article
Poster Session #1: Antibodies and Rejection.
- Published in:
- Pediatric Transplantation, 2017, v. 21, p. 42, doi. 10.1111/petr.12971
- Publication type:
- Article
Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study.
- Published in:
- Pediatric Transplantation, 2017, v. 21, n. 3, p. n/a, doi. 10.1111/petr.12873
- By:
- Publication type:
- Article
Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
- Published in:
- Pediatric Transplantation, 2017, v. 21, n. 2, p. n/a, doi. 10.1111/petr.12847
- By:
- Publication type:
- Article
Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-54140-7
- By:
- Publication type:
- Article
Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib‐containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 12, p. 2387, doi. 10.1111/jcpt.13819
- By:
- Publication type:
- Article
Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 10, p. 1690, doi. 10.1111/jcpt.13723
- By:
- Publication type:
- Article
Successful management of the potentially fatal hyperhaemolysis syndrome of sickle cell anaemia with a regimen including bortezomib and Hemopure.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2019, v. 44, n. 5, p. 815, doi. 10.1111/jcpt.12998
- By:
- Publication type:
- Article
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2018, v. 43, n. 6, p. 914, doi. 10.1111/jcpt.12740
- By:
- Publication type:
- Article
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1398879
- By:
- Publication type:
- Article
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1351565
- By:
- Publication type:
- Article
Daratumumab interference with blood‐compatibility testing after autologous stem cell transplantation.
- Published in:
- Transfusion Medicine, 2023, v. 33, n. 1, p. 92, doi. 10.1111/tme.12948
- By:
- Publication type:
- Article
Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.
- Published in:
- Transfusion Medicine, 2014, v. 24, n. 3, p. 187, doi. 10.1111/tme.12121
- By:
- Publication type:
- Article
The possible involvement of JNK activation in the spinal dorsal horn in bortezomib-induced allodynia: the role of TNF-α and IL-1β.
- Published in:
- Journal of Anesthesia, 2016, v. 30, n. 1, p. 55, doi. 10.1007/s00540-015-2077-x
- By:
- Publication type:
- Article
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2021, v. 11, p. 11, doi. 10.2147/BLCTT.S245191
- By:
- Publication type:
- Article
A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Multiple Myeloma with Foamy Mott Cells.
- Published in:
- Case Reports in Hematology, 2021, p. 1, doi. 10.1155/2021/7391895
- By:
- Publication type:
- Article
Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors.
- Published in:
- Case Reports in Hematology, 2020, p. 1, doi. 10.1155/2020/8821415
- By:
- Publication type:
- Article
Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors.
- Published in:
- Case Reports in Hematology, 2020, p. 1, doi. 10.1155/2020/8821415
- By:
- Publication type:
- Article
Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass.
- Published in:
- Case Reports in Hematology, 2018, p. 1, doi. 10.1155/2018/8606430
- By:
- Publication type:
- Article
Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib.
- Published in:
- Case Reports in Hematology, 2018, p. 1, doi. 10.1155/2018/7063145
- By:
- Publication type:
- Article
The Relationship between Multiple Myeloma with Renal Failure and Metastatic Calcification.
- Published in:
- Case Reports in Hematology, 2018, p. 1, doi. 10.1155/2018/7819792
- By:
- Publication type:
- Article
An integrin β<sub>3</sub>-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
- Published in:
- Nature Cell Biology, 2014, v. 16, n. 5, p. 457, doi. 10.1038/ncb2953
- By:
- Publication type:
- Article
Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
- Published in:
- Lupus, 2017, v. 26, n. 12, p. 1333, doi. 10.1177/0961203317691371
- By:
- Publication type:
- Article
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.
- Published in:
- Lupus, 2017, v. 26, n. 9, p. 952, doi. 10.1177/0961203316686703
- By:
- Publication type:
- Article
Diagnosis and Treatment of AL Amyloidosis.
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 203, doi. 10.1007/s40265-022-01830-z
- By:
- Publication type:
- Article
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
- Published in:
- Drugs, 2019, v. 79, n. 4, p. 447, doi. 10.1007/s40265-019-01080-6
- By:
- Publication type:
- Article
Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
- Published in:
- Drugs, 2019, v. 79, n. 4, p. 353, doi. 10.1007/s40265-019-1065-0
- By:
- Publication type:
- Article